Gracell Biotechnologies acquisition marks China’s growing importance to the Anglo-Swedish drugmaker
AstraZeneca has struck a deal to buy a Chinese cancer therapy company for up to $1.2bn (£950m), as Britain’s biggest drugmaker expands its footprint in its second-largest market.
The Anglo-Swedish pharmaceutical firm announced on Tuesday it would acquire Gracell Biotechnologies, which is focused on a type of cancer therapy known as CAR-T that modifies a patient’s cells to fight the disease.
More Stories
Hyundai facing legal action over car that can be stolen ‘effortlessly in seconds’
Canadian company in negotiations with Trump to mine seabed
UK needs to relax AI laws or risk transatlantic ties, thinktank warns